All Posts: Alzheimer's disease
-
Georgetown’s Memory Disorders Program Marks 20th Year
(April 12, 2019) — When President Ronald Reagan announced in 1994 that he had Alzheimer’s disease, the man known as the “great communicator” tried his best to convey a sense of optimism. “I now begin the journey that will lead me into the sunset of my life. I know that for America there will always […]
Category: GUMC Stories
-
Agent Clears Toxic Proteins, Reduces Inflammation and Improves Cognition in Neurodegeneration Models
LONDON (July 16, 2017) — Researchers have found cell receptors abnormally overexpressed in post-mortem brains of those with Parkinson’s and Alzheimer’s diseases, and that they can be inhibited in animal models to clear toxic protein buildup, reduce brain inflammation, and improve cognitive performance. These dual findings, presented by Georgetown University Medical Center (GUMC) researchers at […]
Category: News Release
-
Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases
Georgetown University today announces it has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.
Category: News Release
-
Georgetown Clinical Trial Testing Nilotinib in Alzheimer’s Disease Begins
A clinical trial to examine the effect of nilotinib on clinical outcomes and biomarkers in people with mild to moderate Alzheimer’s disease has opened at Georgetown University Medical Center (GUMC).
Category: News Release
-
New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment
The following is a press release issued by the ADDF: NEW YORK (September 29, 2016) – The Alzheimer’s Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD,
Category: News Release
-
Georgetown Receives FDA Clearance to Conduct Clinical Trial with Nilotinib in Alzheimer’s Disease
Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer’s disease.
Category: News Release
-
Resveratrol Appears to Restore Blood-Brain Barrier Integrity in Alzheimer’s Disease
TORONTO (July 27, 2016) — Resveratrol, given to Alzheimer’s patients, appears to restore the integrity of the blood-brain barrier, reducing the ability of harmful immune molecules secreted by immune cells to infiltrate from the body into brain tissues, say researchers at Georgetown University Medical Center. The reduction in neuronal inflammation slowed the cognitive decline of patients, […]
Category: News Release
-
More Evidence in Quest to Repurpose Cancer Drugs for Alzheimer’s Disease
TORONTO – An FDA approved drug to treat renal cell carcinoma appears to reduce levels of a toxic brain protein linked to dementia in Alzheimer’s and Parkinson’s diseases when given to animals. This finding is the latest from Georgetown University Medical Center’s Translational Neurotherapeutics Program (TNP) examining tyrosine kinase inhibitors in the treatment of neurodegenerative diseases.
Category: News Release
-
Georgetown Alzheimer’s Researcher Has “BrightFocus”
(June 12, 2016) — Xiong Jiang, PhD, believes there is a way to identify patients at an early enough stage in Alzheimer’s disease — well before clinical symptoms crop up — that they could be effectively treated with novel agents. His ideas have earned him a 3-year $300,000 grant from the BrightFocus Foundation, and on […]
Category: GUMC Stories
-
“SNIFF,” a Nasal Insulin Study for Alzheimer’s, Now Underway at Georgetown
WASHINGTON – Georgetown University’s Memory Disorders Program is looking for volunteers to participate in a study to see if insulin, the hormone used to treat diabetes, can improve cognition, memory and daily function in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Category: News Release